Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier. The closing triggered a $75 million upfront payment. Management projects funding through the end of the first quarter of 2028, including the partnership payment and a completed equity financing raising €30 million in gross proceeds.
The capital provides time to advance clinical programs, but the first patient in the confirmatory Phase 3 TELLOMAK-3 trial is expected only in the first quarter of 2027. The partnership connects financing with a potential route to market. Innate Pharma S.A. (NASDAQ:IPHA) will conduct TELLOMAK-3, while Sobi receives exclusive global commercialization rights upon potential accelerated approval.
Sobi can subsequently assume full global development rights following positive Phase 3 results. That structure could reduce the need for Innate Pharma S.A. (NASDAQ:IPHA) to build a commercial organization independently. Retained milestone and royalty rights also provide participation in lacutamab's success.
Innate Pharma S.A. (NASDAQ:IPHA) is eligible for up to $40 million in near-term development milestones, plus up to $465 million tied to the development-rights option and regulatory and commercial milestones. Tiered double-digit royalties would apply to net sales. These payments offer potential future funding as the program advances.
Spending has also declined. First-half operating expenses fell to €24.7 million from €30.3 million. Lower expenditure gives the new financing a stronger starting point, although future trial activity will determine the spending trajectory.
Other programs provide nearer-term opportunities to demonstrate progress. Innate Pharma S.A. (NASDAQ:IPHA) expects initial Phase 1 data for IPH4502, its Nectin-4 antibody-drug conjugate, in November. The partnered monalizumab program's PACIFIC-9 Phase 3 results are expected in the second half of 2026.
Extract — continue reading at the source.
